drugset / Trial / NCT03934814
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
Timeline
- Start
- 2019-04-16
- Primary completion
- 2023-01-10
- Completion
- 2023-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lemzoparlimab | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | Lemzoparlimab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Lemzoparlimab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Lemzoparlimab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Lemzoparlimab | Monoclonal antibody | 20 mg/kg | — |
| Subject | Lemzoparlimab | Monoclonal antibody | 30 mg/kg | — |
| Subject | Lemzoparlimab | Monoclonal antibody | 45 mg/kg | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |